셀트리온

068270KOSPI

51.6 / 100

Reference Date: 2026-09-08

Financial Score17.5 / 40

News Sentiment19.1 / 25

Momentum6.0 / 20

Disclosure9.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 6.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Celltrion is a global biotech company specializing in developing and commercializing biopharmaceuticals for autoimmune diseases and oncology, with 11 globally approved biosimilar products, including its first biosimilar, Remsima (CT-P13). It has expanded its global presence through strong market dominance in Europe and the U.S., and secured FDA approval for its subcutaneous infliximab formulation in 2023, aiming for 41.625 trillion KRW in sales by 2025.

Number of Employees

3,153people

Average Salary

108.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

39.91Industry Average 15.000.0Point

2.7x industry avg (risky)

PBR

2.50Industry Average 1.200.0Point

2.1x industry avg (risky)

ROE

5.91Industry Average 8.002.5Point

Below industry avg

Debt Ratio

3.05Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20257.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲40.4% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲56.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 4.5% (improving, 3yr)

Detailed News Sentiment

61 totalPositive 47Neutral 11Negative 3Average Sentiment Score 76.4

Positive
바이오시밀러 다음은… 셀트리온 '신약·CDMO' 공략
셀트리온은 바이오시밀러 성공으로 역대 최대 실적을 달성하고 현금흐름을 확대하며 미래 성장동력 확보에 힘쓰고 있다.
Positive
셀트리온 "키트루다·다잘렉스 바이오시밀러, 대상자 줄여 임상 3상 진....
셀트리온의 주요 바이오시밀러 임상 시험 계획 승인으로 인해 긍정적인 시장 반응 예상.
Positive
셀트리온 "키트루다·다잘렉스 3상 IND 변경 승인"
셀트리온의 주요 치료제 키트루다와 다잘렉스의 IND 변경 승인으로 임상 진행에 긍정적 영향 예상.

Detailed Momentum

52-week position3.0Point

52w lower range (29%)

Current 186,300Won52-week high 248,50052-week low 160,500

1-month return2.0Point

1m -6.52% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

11 totalPositive 1Neutral 9Negative 1

Neutral투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 한국 임상 3상 시험계획 변경신청 승인)2026-09-07
Neutral투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 미국 임상 3상 시험계획 변경신청 승인)2026-09-07
Positive주요사항보고서(자기주식취득결정)2026-08-31
Neutral수시공시의무관련사항(공정공시)2026-08-31
Neutral주식등의대량보유상황보고서(일반)2026-08-28